About Kindred Biosciences
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: N/A
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: KIN
- Previous Close: $6.00
- 50 Day Moving Average: $6.10
- 200 Day Moving Average: $5.03
- 52-Week Range: $3.12 - $7.10
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.44
- P/E Growth: -0.35
- Market Cap: $119.35M
- Outstanding Shares: 19,891,000
- Beta: 0.54
- Return on Equity: -33.34%
- Return on Assets: -32.23%
Companies Related to Kindred Biosciences:
- Current Ratio: 23.24%
- Quick Ratio: 23.24%
What is Kindred Biosciences' stock symbol?
Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."
Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?
3 brokers have issued 12 month price objectives for Kindred Biosciences' stock. Their predictions range from $7.00 to $7.50. On average, they anticipate Kindred Biosciences' share price to reach $7.25 in the next year.
When will Kindred Biosciences announce their earnings?
Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
Who owns Kindred Biosciences stock?
Kindred Biosciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (6.71%), EcoR1 Capital LLC (2.87%), Renaissance Technologies LLC (1.77%), Royce & Associates LP (0.74%), Osborn Williams & Donohoe LLC (0.32%) and GRT Capital Partners L.L.C. (0.24%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc and Raymond Townsend.
Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?
Kindred Biosciences' stock was sold by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC and GRT Capital Partners L.L.C..
Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?
Kindred Biosciences' stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP and Renaissance Technologies LLC. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario, Park West Asset Management Llc and Raymond Townsend.
How do I buy Kindred Biosciences stock?
Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Kindred Biosciences stock cost?
One share of Kindred Biosciences stock can currently be purchased for approximately $5.95.